Revision endoscopic sinus surgery rates by chronic rhinosinusitis subtype

• Published in: International forum of allergy & rhinology 2018-09, Vol.8 (9), p.1047-1051
• Main Authors: Miglani, Amar, Divekar, Rohit D., Azar, Antoine, Rank, Matthew A., Lal, Devyani
• Format: Article
• Language: English
• Subjects: allergic fungal sinusitis; Aspirin; aspirin exacerbated respiratory disease; chronic rhinosinusitis; endoscopic sinus surgery; Endoscopy; Granulomatosis; granulomatosis with polyangiitis; Immunodeficiency; Inflammatory diseases; Leukocytes (eosinophilic); nasal polyposis; Nose; Polyps; Respiratory diseases; revision sinus surgery; Rhinitis; Rhinosinusitis; Sinus; Sinusitis; Surgery; Vein & artery diseases
• ISSN: 2042-6976; 2042-6984
• DOI: 10.1002/alr.22146

Background Revision surgery rates following endoscopic sinus surgery (ESS) range between 7% and 50% and are influenced by many factors. This study investigates ESS outcomes for chronic rhinosinusitis (CRS) subtypes. Methods Retrospective review of adult CRS patients undergoing ESS with a single surgeon (2010‐2015) was conducted. Outcomes were analyzed by CRS subtypes. Results ESS was performed in 424 CRS patients (CRS with nasal polyps [CRSwNP], n = 170; CRS without polyps [CRSsNP], n = 254). Most patients (309; 72.9%) could not be specifically subtyped; 115 (27.1%) were subtyped as follows: aspirin‐exacerbated respiratory disease (AERD), n = 47 (11.1%); allergic fungal sinusitis (AFS), n = 39 (9.2%); immunodeficiency, n = 21 (5.0%); granulomatosis with polyangiitis (GPA), n = 5 (1.2%); and eosinophilic granulomatosis with polyangiitis (EGPA), n = 3 (0.7%). All subgroups experienced clinically meaningful reduction in postoperative 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores. At median follow‐up of 28 months (interquartile range [IQR], 10–47 months), 19 patients (4%) underwent revision ESS (CRSwNP, n = 6; CRSsNP, n = 13). Revision ESS rates were 3.5% and 5.1% for CRSwNP and CRSsNP, respectively. Revision ESS rate for subtypes were: AERD 2%; AFS 2%; immunodeficiency 14%; GPA 40%; EGPA 0%; and “all other CRS” 4% at median follow‐up duration of 36, 28, 41, 37, 44, and 26 months, respectively. Conclusion All CRS subtypes demonstrated clinically meaningful improvement in postoperative SNOT‐22 scores following ESS. Our overall revision ESS rate was 4% (3.5% in CRSwNP). AFS, AERD, and EGPA groups demonstrated low revision rates, while immunodeficiency and GPA patients required more revision surgery. A contemporary understanding of CRSwNP subtypes facilitated surgical and medical strategies in improving outcomes for AERD, AFS, and EGPA patients. CRSsNP subtypes with immunodeficiency and GPA merit further investigation to optimize outcomes.